Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupti...
Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulation of HDAC1 in molecular subtypes of breast cancer
About this item
Full title
Author / Creator
Publisher
Sydney: Ivyspring International Publisher Pty Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Sydney: Ivyspring International Publisher Pty Ltd
Subjects
More information
Scope and Contents
Contents
BET bromodomain BRD4 and RAC1 oncogenes are considered important therapeutic targets for cancer and play key roles in tumorigenesis, survival and metastasis. However, combined inhibition of BRD4-RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, HER-2 positive and triple-negative breast (TNBC) largely rema...
Alternative Titles
Full title
Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulation of HDAC1 in molecular subtypes of breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2595660582
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2595660582
Other Identifiers
ISSN
1449-2288
E-ISSN
1449-2288
DOI
10.7150/ijbs.62236
